Rs10757274 gene polymorphisms in coronary artery disease

Abstract

Background: It has been reported the rs10757274 SNP (present on locus 9p21 in the gene for CDKN2BAS1) might be associated with susceptibility to coronary artery disease (CAD). Owing to mixed and inconclusive results, we conducted a meta-analysis to investigate the association between rs10757274 polymorphism and the risk of CAD. Objectives: The present study aimed to investigate the relationship between rs10757274 polymorphism and the risk of CAD. Methods: All studies of the rs10757274 SNP with CAD that were published between 2007 and 2018 were retrieved from the PubMed database. Meta-analysis was performed with Stata 14.0 software. The effect size of the rs10757274 SNP with CAD risk was assessed based on the odds ratios (ORs) with calculation of 95% confidence interval (CI). Results: Eleven studies including 52,209 subjects (cases: 7990, controls: 44,219) were included in the final data combination. Pooled overall analyses showed that rs10757274 (allele model: P < .001; dominant model: P < .001; recessive model: P < .001; Heterozygote codominant: P = .002; Homozygote codominant: P < .001) polymorphisms were significantly associated with the likelihood of CAD. Significant heterogeneity between individual studies appears in all 5 models. Further subgroup analyses revealed that rs10757274 polymorphisms were all significantly correlated with the likelihood of CAD and no heterogeneity were observed in West Asians. Conclusions: Our findings indicated that rs10757274 polymorphisms may serve as genetic biomarkers of CAD, especially in West Asians.

Genetic Association of rs10757278 on Chromosome 9p21 and Coronary Artery Disease in a Saudi Population

“… 31 However, Hu et al 17 and Xu et al 37 conducted meta-analysis studies and concluded that the rs10757278 polymorphism might serve as a genetic marker for CAD. Our research results are in line with the Niemiec et al 35 study, which showed that rs10757278, independent of traditional risk factors, affected CAD susceptibility. 16 , 38–40 In 2011, the rs10757278 polymorphism was first evaluated in a PAGE analysis to assess its association in two populations according to linkage disequilibrium, and the correlation coefficient high.…”

“…The rs10757278 polymorphism shows both positive 35 , 36 and negative associations. 31 However, Hu et al 17 and Xu et al 37 conducted meta-analysis studies and concluded that the rs10757278 polymorphism might serve as a genetic marker for CAD.…”

GATA2 rs2335052 and GATA2 rs78245253 single‐nucleotide polymorphisms in Chinese patients with acute myelocytic leukemia

“…12 More and more evidence indicated that single-nucleotide polymorphism (SNP) might impact the disease's clinical symptoms and prognosis. 13,14 Studies had shown that different genotypes of SNPs were related to the pathogeny and prognosis of AML. [15][16][17] Many SNPs had been identified in the human GATA2 gene, including rs2335052, rs3803, rs2713604 and so on.…”

“…More and more evidence indicated that single‐nucleotide polymorphism (SNP) might impact the disease's clinical symptoms and prognosis 13,14 . Studies had shown that different genotypes of SNPs were related to the pathogeny and prognosis of AML 15‐17 .…”

Health coaching and genetic risk testing in primary care: Randomized controlled trial.

“…Within this chromosomal locus, we chose rs10757274 A/G as the genetic marker for heart disease. Those who carry the minor allele A on rs10757274 at 9p21 have a lower odds ratio (.69-.81) for incident CHD (Xu et al, 2020) and those who carry the risk allele G (vs. A) have a hazard ratio of 1.10 to 1.22 for different racial and ethnic samples (Franceschini et al, 2011). For T2D, the three most highly validated genomic markers at the time of study design were: TCF7L2, KCNJ11, and PPARG (Craddock & Jones, 2007).…”